Multidisciplinary team approach in management of Regorafenib toxicities for patients with metastatic colorectal cancer: Multi-institutional joint research in Shizuoka

Not Applicable

Recruiting

• Conditions: Metastatic colorectal cancer

• Registration Number: JPRN-UMIN000010888
• Lead Sponsor: Shizuoka General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-06-06
• Study Completion: 2015-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1) No Hepatitis virus infection 2) No liver cirrhosis 3) No use of warfarin regularly 4) Patient with active double cancer (synchronous double cancer and metachronous double cancer), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 5) No chronic infection 6) Patient with severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) 7) Pregnant or nursing patient or with intent to bear baby 8) Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduce the regorafenib toxicities by multidisciplinary team approach.

Secondary Outcome Measures

Name	Time	Method
1) Toxicities 2) Dose intensity 3) Response rate, Progression-free survival